All In Biotech

Drug Trial Radar · NCT01411228

A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease

Last checked: Nov 20, 2026Latest source record: Sep 7, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

15

Actual

Start

Sep 2011

Primary completion

Jul 2014

Study completion Aug 2014

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Aug 8, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 2 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A protocol to extend the assessment of the safety and efficacy of taliglucerase alfa in pediatric subjects (2 to \<18 years old) with symptoms and clinical manifestations of Gaucher disease who completed treatment in Protocols PB-06-002 (switchover study from imiglucerase) or PB-06-005 (naïve treatment with taliglucerase alfa).

Conditions

  • Gaucher Disease

Interventions

  • Taliglucerase alfaDrug

    Taliglucerase alfa for infusion every two weeks for 24 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HemoglobinTime frame: Baseline, months 9, 12 and 24

Locations

3 sites in 3 countries. Site status is shown where the registry gives one.

  • Shaare Zedek Medical Center

    Jerusalem, Israel

  • Instituto Privado de Hematologia E Investigacion Clinica (I.P.H.I.C)

    Barrio Asunción, Paraguay

  • Morningside Medi-Clinic

    Morningside, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.